Jounce Therapeutics, Inc. (JNCE): Earnings News

JNCE – Seeing EPS loss beat range from $0.07-$0.20. Misses on revenues.


Key Facts Surrounding This News Item


  • JNCE had a POWR Rating of C (Neutral) coming into today.
  • JNCE was -0.38% below its 10-Day Moving Average coming into today.
  • JNCE was -4.17% below its 20-Day Moving Average coming into today.
  • JNCE was 7.84% above its 50-Day Moving Average coming into today.
  • JNCE was 25.70% above its 100-Day Moving Average coming into today.
  • JNCE was 32.95% above its 200-Day Moving Average coming into today.
  • JNCE had returned +71.29% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Jounce Therapeutics, Inc. (JNCE)


Jounce Therapeutics, Inc. focuses on developing cancer immunotherapy treatments that enable the immune system to attack tumors. The company in 2012 and is based in Cambridge, Massachusetts. View our full JNCE ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

JNCE at a Glance

JNCE Current POWR Rating™
Overall POWR Rating™
JNCE Current Price $6.86 0.58%
More JNCE Ratings, Data, and News

JNCE Price Reaction

The day of this event (Mar. 8, 2018)
JNCE Closing Price$26.08 19.41%
JNCE Volume2,198,900
1,089.24% from avg
Leading up to this event
JNCE 1-mo return9.23%
After this event
JNCE 1-day return12.50%
JNCE 3-day return20.06%
JNCE 5-day return21.64%

JNCE Price Chart



More Jounce Therapeutics, Inc. (JNCE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All JNCE News
Page generated in 1.1178 seconds.